Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Gertjan J L Kaspers"'
Autor:
Dennis S. Metselaar, Aimée du Chatinier, Iris Stuiver, Gertjan J. L. Kaspers, Esther Hulleman
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Metselaar, D S, du Chatinier, A, Stuiver, I, Kaspers, G J L & Hulleman, E 2021, ' Radiosensitization in Pediatric High-Grade Glioma : Targets, Resistance and Developments ', Frontiers in Oncology, vol. 11, 662209 . https://doi.org/10.3389/fonc.2021.662209
Frontiers in Oncology
Metselaar, D S, du Chatinier, A, Stuiver, I, Kaspers, G J L & Hulleman, E 2021, ' Radiosensitization in Pediatric High-Grade Glioma : Targets, Resistance and Developments ', Frontiers in Oncology, vol. 11, 662209 . https://doi.org/10.3389/fonc.2021.662209
Pediatric high-grade gliomas (pHGG) are the leading cause of cancer-related death in children. These epigenetically dysregulated tumors often harbor mutations in genes encoding histone 3, which contributes to a stem cell-like, therapy-resistant pheno
Autor:
Fatma E. El-Khouly, Dannis G. van Vuurden, Thom Stroink, Esther Hulleman, Gertjan J. L. Kaspers, N. Harry Hendrikse, Sophie E. M. Veldhuijzen van Zanten
Publikováno v:
Frontiers in Oncology, 7. Frontiers Media S.A.
Frontiers in Oncology, 7(OCT):254. Frontiers Media S.A.
Frontiers in Oncology, Vol 7 (2017)
Frontiers in Oncology
El-Khouly, F E, van Vuurden, D G, Stroink, T, Hulleman, E, Kaspers, G J L, Hendrikse, N H & Veldhuijzen van Zanten, S E M 2017, ' Effective drug delivery in diffuse intrinsic pontine glioma : A theoretical model to identify potential candidates ', Frontiers in Oncology, vol. 7, no. OCT, 254 . https://doi.org/10.3389/fonc.2017.00254
Frontiers in Oncology, 7(OCT):254. Frontiers Media S.A.
Frontiers in Oncology, Vol 7 (2017)
Frontiers in Oncology
El-Khouly, F E, van Vuurden, D G, Stroink, T, Hulleman, E, Kaspers, G J L, Hendrikse, N H & Veldhuijzen van Zanten, S E M 2017, ' Effective drug delivery in diffuse intrinsic pontine glioma : A theoretical model to identify potential candidates ', Frontiers in Oncology, vol. 7, no. OCT, 254 . https://doi.org/10.3389/fonc.2017.00254
Despite decades of clinical trials for diffuse intrinsic pontine glioma (DIPG), patient survival does not exceed 10% at two years post-diagnosis. Lack of benefit from systemic chemotherapy may be attributed to an intact bloodbrain barrier (BBB). We a